Nestlé Health Science will acquire Aimmune Therapeutics for a total value of $2.6 billion, extending the former's food allergy portfolio.
List view / Grid view
Nestlé Health Science
12 January 2016 | By Victoria White
Nestlé Health Science has signed an exclusive agreement outside the US and Canada for Seres Therapeutics’ Ecobiotics in clostridium difficile infections and inflammatory bowel disease...